Literature DB >> 34418576

Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.

Mohammad Aslam Khan1, Kunwar Somesh Vikramdeo1, Sarabjeet Kour Sudan1, Seema Singh2, Annelise Wilhite3, Santanu Dasgupta2, Rodney Paul Rocconi4, Ajay Pratap Singh5.   

Abstract

Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer, contributing to the high mortality-to-incidence ratio. Management of the platinum-resistant disease has been difficult due to diverse underlying molecular mechanisms. Over the past several years, research has revealed several novel molecular targets that are being explored as biomarkers for treatment planning and monitoring of response. The therapeutic landscape of ovarian cancer is also rapidly evolving, and alternative therapies are becoming available for the recurrent platinum-resistant disease. This review provides a snapshot of platinum resistance mechanisms and discusses liquid-based biomarkers and their potential utility in effective management of platinum-resistant ovarian cancer.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; DNA repair; Epigenetic; Liquid biopsy; Ovarian cancer; Platinum drugs; Platinum resistance

Mesh：

Substances：

Year:  2021        PMID： 34418576      PMCID： PMC8665066          DOI： 10.1016/j.semcancer.2021.08.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  181 in total

1.  Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

Authors:  G S Hagopian; G B Mills; A R Khokhar; R C Bast; Z H Siddik
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

2.  Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.

Authors:  Ayako Kim; Takayuki Enomoto; Satoshi Serada; Yutaka Ueda; Tsuyoshi Takahashi; Barry Ripley; Takashi Miyatake; Masami Fujita; Chun Man Lee; Koji Morimoto; Minoru Fujimoto; Tadashi Kimura; Tetsuji Naka
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

Review 3.  Glutathione levels in human tumors.

Authors:  Michael P Gamcsik; Mohit S Kasibhatla; Stephanie D Teeter; O Michael Colvin
Journal:  Biomarkers       Date:  2012-08-20       Impact factor: 2.658

4.  Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.

Authors:  Girijesh Kumar Patel; Mohammad Aslam Khan; Arun Bhardwaj; Sanjeev K Srivastava; Haseeb Zubair; Mary C Patton; Seema Singh; Moh'd Khushman; Ajay P Singh
Journal:  Br J Cancer       Date:  2017-02-02       Impact factor: 7.640

5.  Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses.

Authors:  Zhonghua Chen; Xiaoli Guo; Shukai Sun; Caixia Lu; Liming Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

6.  BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.

Authors:  Xuefeng Bai; Yingzi Fu; Hui Xue; Kejun Guo; Zhiguo Song; Zhaojin Yu; Tianhong Jia; Yuanyuan Yan; Lin Zhao; Xiaoyi Mi; Enhua Wang; Zhihong Zheng; Haishan Zhao; Weifan Yao; Minjie Wei
Journal:  Oncol Lett       Date:  2014-02-13       Impact factor: 2.967

7.  ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.

Authors:  Erhong Meng; Aparna Mitra; Kaushlendra Tripathi; Michael A Finan; Jennifer Scalici; Steve McClellan; Luciana Madeira da Silva; Eddie Reed; Lalita A Shevde; Komaraiah Palle; Rodney P Rocconi
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

8.  Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer.

Authors:  Jia Liu; Lin Zhang; Ping Mao; Guoqiang Jiang; Likun Liu; Jing Wang; Wei Yang; Lawrence Owusu; Weiling Li
Journal:  Oncotarget       Date:  2017-08-24

9.  Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer.

Authors:  Asami Ikeda; Ken Yamaguchi; Hajime Yamakage; Kaoru Abiko; Noriko Satoh-Asahara; Kenji Takakura; Ikuo Konishi
Journal:  Obstet Gynecol Sci       Date:  2020-09-17
View more
  5 in total

Review 1.  Emerging role of m6A methylation modification in ovarian cancer.

Authors:  Lin-Lin Chang; Xia-Qing Xu; Xue-Ling Liu; Qian-Qian Guo; Yan-Nan Fan; Bao-Xia He; Wen-Zhou Zhang
Journal:  Cancer Cell Int       Date:  2021-12-11       Impact factor: 5.722

2.  Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.

Authors:  Yongmei Li; Yufei Nie; Hongyan Guo; Hua Guo; Chunfang Ha; Yuan Li
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

3.  The Long Non-Coding RNA SNHG12 as a Mediator of Carboplatin Resistance in Ovarian Cancer via Epigenetic Mechanisms.

Authors:  Cecilie Abildgaard; Luisa Matos do Canto; Cláudia Aparecida Rainho; Fabio Albuquerque Marchi; Naiade Calanca; Marianne Waldstrøm; Karina Dahl Steffensen; Silvia Regina Rogatto
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

4.  The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.

Authors:  Francesco Morra; Francesco Merolla; Giovanna Damia; Francesca Ricci; Silvia Varricchio; Gennaro Ilardi; Laura Arenare; Daniela Califano; Virginia Napolitano; Robert Fruscio; Rosa Marina Melillo; Luca Palazzo; Angela Celetti
Journal:  J Exp Clin Cancer Res       Date:  2022-08-13

5.  Ovarian cancer resistance to PARPi and platinum-containing chemotherapy.

Authors:  Rebekah Summey; Denise Uyar
Journal:  Cancer Drug Resist       Date:  2022-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.